EUVIMEDEUVIMED entdecken
Crossref

AB001. Comparison of the performance of clinical classification systems for myasthenia gravis relapse after thymoma resection

Zhiheng Yao, Hongmu Li, Zhenyuan Yang, Yu Huang, Leqi Zhong, Zhenyu Zhao, Yiling Cai, Chun Chen, Bin Zheng

Mediastinum · 2026-10 · 10 · AB001-AB001

DOI: 10.21037/med-26-ab001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mediastinum, 2026-10. Verfasst von Zhiheng Yao und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Neurologic outcomes after thymoma resection in patients with myasthenia gravis (MG) are heterogeneous. We aimed to characterize clinically significant MG relapse/exacerbation after thymoma resection and compare classification systems for risk stratification. METHODS: This multicenter retrospective cohort included 257 patients with thymoma-associated MG who underwent extended thymectomy at 3 centers from July 2009 through November 2025. The end point was new MG symptoms after postoperative complete stable remission, pharmacologic remission, or minimal manifestation status plus verifiable MG-related treatment escalation or rescue therapy. Death without MG relapse/exacerbation was treated as a competing event. Cumulative incidence functions were estimated with Aalen-Johansen and compared with Gray tests; predictors were assessed with Fine-Gray models. RESULTS: During median follow-up of 41.6 months, 69 relapse/exacerbation events and 21 competing deaths occurred. Cumulative incidence was 20.4% at 3 years and 29.0% at 5 years; 68% and 90% of events occurred within 3 and 5 years, respectively. Among 52 relapse/exacerbation events in patients who underwent surgery in 2018 or later with retrievable treatment-status data, 28 (53.8%) occurred during ongoing immunosuppression and 24 (46.2%) after withdrawal. The a/b phenotype-based grouping of the Myasthenia Gravis Foundation of America classification (1/A/B) showed the strongest separation (3-year cumulative incidences, 2.5%, 12.3%, and 56.4%; 5-year cumulative incidences, 7.6%, 29.6%, and 56.4% for groups 1, A, and B). Groups A and B were independently associated with relapse/exacerbation (subdistribution hazard ratio, 2.65; 95% CI: 1.18–5.91; and 10.55; 95% CI: 4.55–24.47). CONCLUSIONS: Clinically significant MG relapse/exacerbation after thymoma resection clustered in the early postoperative years. The a/b phenotype-based grouping of the Myasthenia Gravis Foundation of America classification (1/A/B) provided the most informative risk stratification. The study has been officially published in JTCVS Open (2026;33:101980; doi:10.1016/j.xjon.2026.101980).

Zitieren

APA

Yao, Z., Li, H., Yang, Z., Huang, Y., Zhong, L., Zhao, Z., Cai, Y., Chen, C., & Zheng, B. (2026). AB001. Comparison of the performance of clinical classification systems for myasthenia gravis relapse after thymoma resection. Mediastinum, 10, AB001-AB001. https://doi.org/10.21037/med-26-ab001

Vancouver

Yao Z, Li H, Yang Z, Huang Y, Zhong L, Zhao Z, et al. AB001. Comparison of the performance of clinical classification systems for myasthenia gravis relapse after thymoma resection. Mediastinum. 2026;10:AB001-AB001. doi:10.21037/med-26-ab001

BibTeX
@article{Yao2026,
  author = {Yao, Zhiheng and Li, Hongmu and Yang, Zhenyuan and Huang, Yu and Zhong, Leqi and Zhao, Zhenyu and Cai, Yiling and Chen, Chun and Zheng, Bin},
  title = {AB001. Comparison of the performance of clinical classification systems for myasthenia gravis relapse after thymoma resection},
  journal = {Mediastinum},
  year = {2026},
  volume = {10},
  pages = {AB001--AB001},
  doi = {10.21037/med-26-ab001}
}
Kostenlos starten →